Analyst Upgrades

• Las Vegas Sands (LVS) to outperform from neutral at Credit Suisse.
• Boston Scientific (BSX) to outperform from sector perform at RBC Capital.
• Windstream (WIN) to buy from hold at Citigroup.
• Expeditors (EXPD) to buy from neutral at UBS.
• A123 Systems (AONE) to neutral from underperform and Chesapeake Midstream (CHKM) to buy from neutral at BofA/Merrill.
• AvalonBay (AVB) to outperform from neutral and Post Properties (PPS) to neutral from underperform at Cowen.

Continue reading Analyst Calls: AONE, AVB, BSX, LVS, MDRX, RRC, SAP, TIVO, WIN ...

Analyst Calls: AONE, AVB, BSX, LVS, MDRX, RRC, SAP, TIVO, WIN ... originally appeared on BloggingStocks on Tue, 01 Mar 2011 11:40:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Boeing (BA) to overweight from neutral at JPMorgan.
• Alcoa (AA) to buy from hold at Deutsche Bank.
• BP (BP) to outperform from market perform at Raymond James.
• Office Depot (ODP) and Staples (SPLS) to buy from neutral at Janney Capital.
• ON Semiconductor (ONNN) to buy from hold at Citigroup.
• Kennametal (KMT) and Polyone (POL) to buy from hold at KeyBanc.
• Airgas (ARG) to outperform from market perform at William Blair.
• EchoStar (SATS) to neutral from underperform at Macquarie.

Continue reading Analyst Calls: AA, BA, BP, BSX, COH, GM, INTC, NSM, STJ, TIF, TSN, UA ...

Analyst Calls: AA, BA, BP, BSX, COH, GM, INTC, NSM, STJ, TIF, TSN, UA ... originally appeared on BloggingStocks on Mon, 03 Jan 2011 11:40:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Goldman upgraded Jones Lang LaSalle (JLL) to buy from neutral.
• Credit Suisse upgraded Pulte Group (PHM) to neutral from underperform. Note that Citigroup downgraded the stock.
• Ameristar Casinos (ASCA) was upgraded to neutral from sell at Merriman.
• Citigroup upgraded Kimco Realty (KIM) to hold from sell.
• Mistras (MG) was upgraded to buy from hold at KeyBanc.
• Devon Energy (DVN) was upgraded to outperform from neutral at Macquarie.
• Garmin (GRMN) was upgraded to outperform from sector perform at PacCrest.

Continue reading Analyst Calls: AAPL, AMGN, BIIB, BSX, CHK, DVN, EOG, GRMN, PHM, WPO ...

Analyst Calls: AAPL, AMGN, BIIB, BSX, CHK, DVN, EOG, GRMN, PHM, WPO ... originally appeared on BloggingStocks on Thu, 04 Nov 2010 11:30:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• JMP Securities upgraded Hewlett-Packard (HPQ) to outperform from market perform based on valuation and checks that indicate strength in enterprise PCs, high growth geographies and light laptops. The firm has a $50 target on the stock.
• RBC Capital upgraded Rio Tinto (RTP) to outperform from sector perform, citing the company's improving growth plans and attractive risk profile.
• Goldman upgraded FormFactor (FORM) to neutral from sell, but lowered its price target to $6 from $10. The firm cites valuation for the upgrade.
• MCG Capital (MCGC) was upgraded to outperform from market perform at FBR Capital.
• CRH (CRH) was upgraded to neutral from underweight at JPMorgan.
• Melco Crown (MPEL) was upgraded to overweight from equal weight at Morgan Stanley.

Continue reading Analyst Calls: BSX, FORM, HPQ, JACK, MCO, NFLX, PPL, RTP, VALE ...

Analyst Calls: BSX, FORM, HPQ, JACK, MCO, NFLX, PPL, RTP, VALE ... originally appeared on BloggingStocks on Thu, 02 Sep 2010 11:30:00 EST. Please see our terms for use of feeds.

Continue reading Should You Avoid Medtronic?

Should You Avoid Medtronic? originally appeared on BloggingStocks on Fri, 27 Aug 2010 09:00:00 EST. Please see our terms for use of feeds.

Continue reading Boston Scientific to Pull Defibrillators

Boston Scientific to Pull Defibrillators originally appeared on BloggingStocks on Tue, 16 Mar 2010 10:00:00 EST. Please see our terms for use of feeds.

Continue reading Boston Scientific to Pay Johnson & Johnson $1.7B Settlement

Boston Scientific to Pay Johnson & Johnson $1.7B Settlement originally appeared on BloggingStocks on Mon, 01 Feb 2010 14:10:00 EST. Please see our terms for use of feeds.

Insurance companies just bought themselves a year. Claiming that a proposed tax on health insurance would force them to charge higher premiums, carriers were able to convince senators to defer this particular measure for a year.

This comes as a benefit to UnitedHealth Group (UNH), WellPoint (WLP) and smaller companies writing health insurance policies. Manufacturers of medical devices have won some relief, as well, though the drug business didn't. An earlier plan to tax cosmetic medical procedures was also scrapped.

Continue reading Health Insurers Get Brief Relief on Proposed Tax

Health Insurers Get Brief Relief on Proposed Tax originally appeared on BloggingStocks on Mon, 21 Dec 2009 09:00:00 EST. Please see our terms for use of feeds.

Medtronic (NYSE: MDT), a manufacturer of a whole host of medical devices involved with the management of diabetes and cardiovascular disease, released its Q1 data on Tuesday. Revenues increased 6%, and adjusted earnings per share came in at 79 cents (some of the adjustments were related to restructuring and litigation issues).

The company was able to grow the adjusted-per-share bottom line by 10%. In addition, according to Reuters, Medtronic beat estimates by a penny. Shareholders should keep in mind, however, that the quarter benefited from an extra week.

Continue reading Medtronic increases adjusted income, beats by a penny

Medtronic increases adjusted income, beats by a penny originally appeared on BloggingStocks on Wed, 26 Aug 2009 11:00:00 EST. Please see our terms for use of feeds.

Here are some highlights from last week's earnings coverage from BloggingStocks:

• AK Steel Holding Corp. (NYSE: AKS) posted a smaller-than-expected Q2 net loss as steel prices rise.
• Boston Scientific Corp. (NYSE: BSX) posted a better-than-expected Q2 profit on strong overseas sales.
• Caterpillar Inc. (NYSE: CAT) shares jumped after it beat earnings, missed revenues, and offered guidance.
• DuPont (NYSE: DD) shares declined after it posted a higher-than-expected profit but lower revenue.
• Eaton Corp. (NYSE: ETN) disappointing results were a sign that the bulls are in charge, said Jim Cramer.
• General Electric Co. (NYSE: GE) Q2 earnings and sales declined, dragged down by finance and NBC units.

Continue reading Earnings highlights: Caterpillar, DuPont, GE, Halliburton, Texas Instruments ...

Earnings highlights: Caterpillar, DuPont, GE, Halliburton, Texas Instruments ... originally appeared on BloggingStocks on Sat, 25 Jul 2009 15:40:00 EST. Please see our terms for use of feeds.

Boston Scientific (NYSE: BSX), an expert in medical devices and a colleague of Johnson & Johnson (NYSE: JNJ), reported earnings for the second quarter on Monday after the closing bell. Wall Street liked the results. Shares of the company were bid higher by 5.8% in the after-hours session.

Net sales increased 7%. On an adjusted basis, Boston Scientific made 20 cents per share. According to Earnings.com, the business was supposed to bring in only 13 cents per share. Thus, management did a superb job of beating the analysts at their precious game. Unfortunately, Boston Scientific made the same amount of adjusted profit in the year-ago period, so there wasn't any growth on the bottom line.

Continue reading Boston Scientific tops estimates and guides higher

Boston Scientific tops estimates and guides higher originally appeared on BloggingStocks on Tue, 21 Jul 2009 09:00:00 EST. Please see our terms for use of feeds.

• Deutsche Bank upgraded Spartech (NYSE: SEH) to Buy from Hold as it sees further upside following the company's "strong" Q2 results. The firm raised its target on shares to $10 from $2.50.
• Oppenheimer upgraded Clorox (NYSE: CLX) to Outperform from Underperform. The firm believes the company's FY10 outlook is conservative, providing room for upside, and that the valuation is compelling at current levels. Opco set a $70 price target on the stock.
• Goldman upgraded Steel Dynamics (NASDAQ: STLD) to Buy from Neutral and raised its target to $20 from $16, citing reduced balance sheet concerns following the capital raise. Note that AK Steel (NYSE: AKS) was downgraded to Neutral from Buy.
• PG&E (NYSE: PCG) was upgraded to Buy from Hold at Citigroup.
• Pool Corp. (NASDAQ: POOL) was upgraded to Outperform from Market Perform at William Blair.
• Liberty Property Trust (NYSE: LRY) was upgraded to Outperform from Market Perform at Wachovia.

Continue reading Analyst upgrades, downgrades and initiations: CLX, ED, JBHT, HMC, PCG ...

Analyst upgrades, downgrades and initiations: CLX, ED, JBHT, HMC, PCG ... originally appeared on BloggingStocks on Fri, 12 Jun 2009 11:20:00 EST. Please see our terms for use of feeds.

Analyst upgrades:

• Jefferies upgraded Aruba Networks (NASDAQ: ARUN) to Buy from Hold following the company's Q3 results to reflect improved visibility. The firm raised its target price to $6.50 from $3.
• Citigroup upgraded Mosaic (NYSE: MOS) and Potash (NYSE: POT) to Buy from Hold and Agrium (NYSE: AGU) to Hold from Sell as it believes stronger grain fundamentals more than offset China contract risk. The firm raised its target on Mosaic to $72 from $48, on Potash to $145 from $83 and on Agrium to $55 from $36.
• Fulton Financial (NASDAQ: FULT) Was upgraded to Market Perform from Underperform at Keefe Bruyette.
• Rio Tinto (NYSE: RTP) was raised to Neutral from Sell at Goldman.
• Noble Corp. (NYSE: NE) was upgraded at Deutsche Bank to Buy from Hold.

Continue reading Analyst upgrades, downgrades and initiations: ARUN, MOS, POT, AGU, EGLE, DO, MON, SWCEY, TDC and ABC

Analyst upgrades, downgrades and initiations: ARUN, MOS, POT, AGU, EGLE, DO, MON, SWCEY, TDC and ABC originally appeared on BloggingStocks on Fri, 22 May 2009 10:00:00 EST. Please see our terms for use of feeds.

Continue reading Abbott Labs (ABT) gains on stent study results

Abbott Labs (ABT) gains on stent study results originally appeared on BloggingStocks on Mon, 30 Mar 2009 12:20:00 EST. Please see our terms for use of feeds.

Abbott Laboratories (NYSE: ABT) got approval for its new drug-coated stent. The products are used to open clogged arteries, often in the place of by-pass surgery. The field has been dominated by deeply troubled medical device company Boston Scientific (NYSE: BSX). It looks that the weakened company is in for much more pain.

According to The Wall Street Journal, ABT "received regulatory approval for its Xience V drug-coated stent, which is expected to be the top seller in the roughly $2 billion U.S. market because it appears to be more effective than rival devices." Boston Scientific will sell the new Abbott product, but with 40% of the revenue going to its rival, it is hard to see how that is a good deal.

BSX has been beaten by competition at almost every turn. It took on tremendous debt when it bought medical device company Guidant. It faced trouble when some Guidant products hit quality control issues. Boston Scientific stents came under criticism a year ago, when medical research questioned how effective they were.

BSX traded at almost $45 in 2004. It is now at about $12. With new competition and a bad balance sheet, that is not likely to change much.

Douglas A. McIntyre is an editor at 247wallst.com.

Abbott's success is Boston Scientific's failure originally appeared on BloggingStocks on Thu, 03 Jul 2008 09:40:00 EST. Please see our terms for use of feeds.

Recent data suggests that America's largest industrial companies are piling up cash. The New York Times reports: "According to S.& P., the total cash held by companies in its industrial index exceeded $600 billion in February, up from about $203 billion in 1998."

That is good news if the money does something other than sit in the bank. A number of very large companies like Google (NASDAQ: GOOG) don't need anywhere near the tons of greenbacks in their accounts and they add more every quarter.

The money probably has two potential uses. One is to buy other companies -- as the market falls, there are going to be more deals at lower prices. Of course, many deals don't work. Some of these will fail to find economies of scale and lead to write-offs like the Boston Scientific (NYSE: BSX) buyout of Guidant. Everyone lost as the BSX shares fell apart.

The second option is that companies could just do the simple thing and turn the cash back to shareholders. Everyone wins and it is hard to screw up a big one-time dividend.

Douglas A. McIntyre is an editor at 247wallst.com

America's big companies have a lot of cash originally appeared on BloggingStocks on Tue, 04 Mar 2008 11:11:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Credit Suisse initiated the medical supplies and devices sector with a Market Weight rating and started shares of Edwards Lifesciences (NYSE: EW) and Becton, Dickinson and Co (NYSE: BDX) with Outperform ratings and Medtronic (NYSE: MDT) and Boston Scientific (NYSE: BSX) with Neutral ratings.
  
• East West Bancorp (NASDAQ: EWBC) was initiated with a Buy rating and $36 target at B. Riley; the firm's target implies a 23.1% potential total return over the next twelve months including the stock's 1.35% dividend yield.
  
• Tempur Pedic (NYSE: TPX) was started with an Outperform rating at William Blair, as they find the current valuation attractive for long-term investor given the company's strong position in the specialty sleep products.
  
• Deutsche Bank resumed coverage of AbitibiBowater (NYSE: ABH) with a Hold rating and $29 target, citing the strength of the Canadian dollar and difficult newsprint fundamentals.

• Banc of America initiated shares of JA Solar (NASDAQ: JASO) and Trina Solar (NYSE: TSL) with Buy ratings and targets of $73 and $76, and initiated Horizon Lines (NYSE: HRZ) and Solarfun Power (NASDAQ: SOLF) with Neutral ratings and targets of $34 and $14.

Analyst initiations: Medical supples and devices sector, EWBC, TPX and ABH originally appeared on BloggingStocks on Wed, 07 Nov 2007 10:50:00 EST. Please see our terms for use of feeds.

Boston Scientific (NYSE: BSX) is a company in trouble. It spent too much for medical device company Guidant, leaving it with $8.3 billion in debt. And sales of its drug-coated stents have been hurt by clotting problems. The company lost $272 million in the last quarter.

The combination of high debt and poor earnings has done a great deal of damage to the stock. The company's shares are down about 22% this year.

Boston Scientific has come up with a simple plan, which is to sell itself off in pieces until its debt comes down to a level that it can service. Today, the company sold its cardiac surgery and vascular surgery units for $750 million. The buyer was Getinge, a Swedish company. The two units were part of Guidant.

The announcement is another example of the hideous cycle that begins when companies overreach. From late 2003 to early 2005, before BSX bought Guidant and took on mountains of debt, its shares moved from $13 to $35. Earnings were strong and shareholders were happy. But BSX management could not resist buying another medical device company and got into a brutal bidding war with Johnson & Johnson (NYSE: JNJ), which pushed the price of Guidant to an irrational level.

Now, Boston Scientific can sell off what it bought, but probably at a lower price.

Douglas A. McIntyre is an editor at 247wallst.com.

Boston Scientific unit sale digs it out of hole originally appeared on BloggingStocks on Mon, 05 Nov 2007 06:10:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Goldman removed shares of Air France (NYSE: AKH) from its Conviction Buy List due to the increase in the price of fuel and the possibility of an economic slowdown.
  
• Goldman downgraded BHP Billiton (NYSE: BHP) to Neutral from Buy and removed the stock from its Pan-Europe Buy List due to valuation.
  
• Merrill Lynch downgraded shares of AstraZeneca (NYSE: AZN) to Sell from Neutral to reflect increased competition from generic-drug makers, a poor pipeline and slow earnings growth.
  
• Wachovia downgraded shares of Broadcom Corporation (NASDAQ: BRCM) to Hold from Buy to reflect valuation and the company's lower than expected Q3 results. Shares were also lowered to Hold from Buy at Deutsche Bank.
  
• Stanford lowered Savvis (NASDAQ: SVVS) to Hold from Buy and notes that the company's Q3 results and Q4 revenue guidance brings the company's 2007 revenue outlook $15M below the consensus, and advises investors to remain on the sidelines. The firm believes the company's strategy is sound, but that its execution has been slow.

• Blockbuster (NYSE: BBI) and Akzo Nobel (OTC: AKZOY) were downgraded to Neutral from Overweight at JP Morgan.
  
• Friedman Billings downgraded the E&P sector, including Brigham Exploration Company (NASDAQ: BEXP), Mariner Energy (NYSE: ME) and Nobel Energy (NYSE: NBL) to Market Perform from Outperform.
  
• Baird downgraded Plantronics (NYSE: PLT) to Neutral from Outperform.
  
• Goldman downgraded Boston Scientific (NYSE: BSX) to Neutral from Buy.

Analyst downgrades: AKH, BHP, AZN, BRCM and SVVS originally appeared on BloggingStocks on Wed, 24 Oct 2007 11:17:00 EST. Please see our terms for use of feeds.

Another earnings season crunch is under way, and here are a some highlights of this past week's earnings coverage here at BloggingStocks:

• Advanced Micro Devices (NYSE: AMD) reported losses 9 cents greater than Wall Street estimates.
• Altria Group Inc.'s (NYSE: MO) profits were down, but the company raised its full-year earnings guidance.
• Bank of America Corp. (NYSE: BAC) fell short of expectations, profits down 32%.
• Boston Scientific Corp. (NYSE: BSX) almost tripled Wall Street's earnings estimates.
• Citigroup Inc. (NYSE: C) had warned to expect a disappointing results, and earnings per share fell 57%.
• Coca-Cola Co. (NYSE: KO) beat estimates, sending the share price to a 52-week high.
• Domino's Pizza Inc. (NASDAQ: DPZ) fell short of expectations, profits falling 55%.
• eBay Inc.'s (NASDAQ: EBAY) otherwise good results were hurt by Skype-related losses.
• Gannett Inc.'s (NYSE: GCI), earnings beat expectations but revenue fell short.
• Genetech Inc. (NYSE: DNA) beat estimates by a penny, but analysts' concerns linger.
• Google Inc. (NASDAQ: GOOG) had a spectacular third quarter. See our live blog of the conference call.

Continue reading Earnings highlights: Tech stocks strong, financials weak

Earnings highlights: Tech stocks strong, financials weak originally appeared on BloggingStocks on Sat, 20 Oct 2007 12:40:00 EST. Please see our terms for use of feeds.